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Abstract
Background—Bisphenol A (BPA) is a widely used industrial chemical and suspected endocrine 
disruptor to which humans are ubiquitously exposed. Liver metabolizes and facilitates BPA 
excretion through glucuronidation and sulfonation. The sulfotransferase enzymes contributing to 
BPA sulfonation (detected in human and rodents) is poorly understood.
Objectives—To determine the impact of metabolic and liver disease on BPA sulfonation in 
human and mouse livers.
Methods—The capacity for BPA sulfonation was determined in human liver samples that were 
categorized into different stages of metabolic and liver disease (including obesity, diabetes, 
steatosis, and cirrhosis) and in livers from ob/ob mice.
Results—In human liver tissues, BPA sulfonation was substantially lower in livers from subjects 
with steatosis (23%), diabetes cirrhosis (16%), and cirrhosis (18%), relative to healthy individuals 
with non-fatty livers (100%). In livers of obese mice (ob/ob), BPA sulfonation was lower (23%) 
than in livers from lean wild-type controls (100%). In addition to BPA sulfonation activity, 
Sult1a1 protein expression decreased by 97% in obese mouse livers.
Conclusion—Taken together these findings establish a profoundly reduced capacity of BPA 
elimination via sulfonation in obese or diabetic individuals and in those with fatty or cirrhotic 
livers versus individuals with healthy livers.
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Introduction
Bisphenol A is an industrial chemical and suspected endocrine disruptor with a widespread 
exposure in humans. Urinary BPA (total, indicating free BPA plus BPA-conjugates) has 
been detected at a mean of 2.6 μg/L in ~96% of samples from 2011–2012 NHANES study 
conducted by the Center of Disease Control (CDC) (http://wwwn.cdc.gov/nchs/nhanes/
2011-2012/EPH_G.htm), as well as fetus, adult blood and placenta (Volkel et al., 2002). 
According to the most recent U.S. Food and Drug Administration (FDA) update, the average 
dietary exposure of BPA from food is estimated to be 0.2–0.4 microgram per kilogram body 
weight per day (μg/kg bw/day) for infants and 0.1–0.2 μg/kg bw/day for children and adults 
(FDA, 2010). Although human exposure to BPA is widespread, studies report a wide range 
of effective concentrations for specific pathways of BPA mediated endocrine disruption 
such as estrogenicity, aromatase and androgen receptor inhibition (Judson et al., 2010; Reif 
et al., 2010).
BPA is predominantly metabolized in the liver to corresponding glucuronide and sulfate 
conjugates (Pritchett et al., 2002; Hanioka et al., 2008). In both humans and rodents, BPA-
glucuronide is the major metabolite detected in blood and urine, whereas sulfated conjugates 
(mono- and di-sulfates) are minor metabolites (Nishiyama et al., 2002; Volkel et al., 2002; 
Teeguarden et al., 2015; Thayer et al., 2015). Glucuronide and sulfate conjugated BPA 
metabolites are eliminated from the body into the urine via glomerular filtration. In addition, 
in rodents biliary excretion of BPA-glucuronide into the feces is substantial. In vitro ATPase 
activity assays have demonstrated that BPA-glucuronide has a high affinity for rodent Mrp2 
and human MRP3 (ABCC3, basolateral) but is a non-substrate for human MRP2 (ABCC2, 
apical) transporters (Mazur et al., 2012). In rats, conjugated and unconjugated BPA is 
primarily (~66%) disposed through biliary excretion and detected in feces 6 hrs after oral or 
i.v administration (Kurebayashi et al., 2003) potentially due to high BPA-G affinity to Mrp2. 
In rats administered BPA, ~81% of administered dose was detected (measured as total BPA- 
conjugated and unconjugated) in feces, ~16% in urine while ~0.1% accumulated in tissue. 
However, urinary excretion is the major route of BPA elimination from the body in humans, 
which have higher affinity of BPA-G to basolateral MRP3 and relatively low affinity to 
apical MRP2 (Mazur et al., 2012). Conjugated BPA (glucuronide/sulfate) may be de-
conjugated in the intestinal tract by glucuronidases/sulfatases and undergo enterohepatic 
recirculation that has been reported in rodents, but not humans (Ginsberg and Rice, 2009).
BPA-sulfate metabolites are detected in human serum and urine at a geometric mean of 
0.124 ng/mL and 0.104 ng/mL, respectively (Liao and Kannan, 2012) with females having 
lower glucuronidated and higher sulfated BPA conjugates relative to males (Kim et al., 
2003; Kurebayashi et al., 2003; Ye et al., 2005). BPA sulfonation is potentially SULT1A1-
mediated, as determined using in vitro enzymatic methods (Nishiyama et al., 2002). 
However, the majority of studies describing BPA sulfonation utilize recombinant enzyme 
systems to determine BPA sulfonation by SULTs, and further studies are needed to 
determine and confirm BPA sulfonation in human liver.
Rodent studies and human epidemiological studies have revealed a significant correlation 
between BPA exposure and endocrine disruption, reproductive and developmental defects in 
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rodents, as well as with metabolic disorders such as hypertension, diabetes and obesity 
(Christiansen et al., 2014; Khalil et al., 2014; Alonso-Magdalena et al., 2015). Extrapolation 
of observed BPA effects in rodents to humans is controversial, although building evidence 
suggests refinement of risk assessment towards more vulnerable populations such as fetuses, 
infants (Myers et al., 2009; Valentino et al., 2015) and potentially disease states with 
compensated liver function. Two studies have demonstrated ability of BPA to promote lipid 
accumulation in hepatocytes (Huc et al., 2012; Wang et al., 2013); the effect of this 
morphological and phenotypic change on BPA metabolism needs to be explored.
Non Alcoholic Fatty Liver Disease (NAFLD) is the accumulation of lipids exceeding 5% by 
weight of hepatocytes. NAFLD has also been referred to as “hepatic manifestation of insulin 
resistance” ranging from steatosis (fatty liver) to non-alcoholic steatohepatitis (fatty liver 
with liver cell damage and inflammation) to progressive hepatic fibrosis, cirrhosis and 
hepatocellular carcinoma (McCullough, 2011). In the United States, prevalence of NAFLD 
alone or in combination with increased liver enzymes in serum, as diagnosed by various 
techniques, was between 5–33% among adults (Lazo and Clark, 2008). Studies have shown 
that expression of several drug metabolism enzymes and transporters is altered in humans 
and rodent models of nonalcoholic fatty liver disease (steatosis) and obesity (Merrell and 
Cherrington, 2011). In addition, our recent studies showed that SULT1A1 expression and 
activity with a probe substrate was reduced in steatosis, diabetic cirrhosis, and alcoholic 
cirrhosis (Hardwick et al., 2013; Yalcin et al., 2013). This may result in modified 
metabolism and disposition of BPA, and potentially modified toxicity and adverse effects.
While sulfotransferase enzymes are an important class of Phase-II detoxification enzymes 
known to metabolize endogenous and xenobiotic compounds (James and Ambadapadi, 
2013), sulfotransferase expression and activity for BPA has not been characterized in human 
livers under diseased conditions. Although secondary to glucuronidation, repression of 
SULT1A1 and SULT1A3 protein and activity in diseased human livers (Yalcin et al., 2013) 
points towards a potentially decreased ability for BPA biotransformation in the diseased 
liver. The purpose of this study herein was to characterize BPA sulfonation and SULT1A1 
expression in human livers from individuals diagnosed with metabolic or liver disease, as 
well as in the ob/ob mouse under normal and fasted conditions to model metabolic-induced 
fatty liver disease. Herein, we describe decreased BPA sulfonation in diseased livers from 
both humans and mice.
Materials and Methods
Chemicals
[35S]PAPS (1.5–2.54 Ci/mmol) and scintillation fluid (Ultima Flo-M) were purchased from 
PerkinElmer Life and Analytical Sciences. p-Nitrophenol, and BPA were purchased from 
Sigma Aldrich. Sult1a1 antibody was obtained from Santa Cruz Biotechnology (TX, USA) 
and Gapdh antibody was obtained from Cell Signaling Technologies (MA, USA).
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Animal treatment and fasting
Adult male C57BL/6 (WT, n=6–8/group) and Lep−/− (B6.V-Lepob/J, ob/ob, n=6–8/group) 
mice (Jackson Laboratories, Bar Harbor, ME, USA) were fed Harlan TekladLM-485 
Mouse/Rat sterilizable diet or food-withheld for 24 hrs. Mice were housed in a temperature-, 
light-, and humidity-controlled environment in cages with corncob bedding. All the animal 
experiments were carried at University of Rhode Island, Fogarty facility with IACUC 
approval. Livers were collected, snap frozen in liquid nitrogen, and stored in −80°C until 
further analysis.
Cytosol isolation from human and mouse liver tissue
Human liver tissues were purchased from Liver Tissue Cell Distribution System (LTCDS), 
University of Minnesota, Minneapolis, MN. Details of the human liver donors are described 
in Yalcin et al. 2013. Liver samples were stored frozen at −80°C until the cytosolic fractions 
were prepared. Method for isolating cytosolic fractions has been reported previously (Yalcin 
et al., 2013). Briefly, liver tissue was homogenized by sonication in buffer containing 
sucrose/Tris/EDTA buffer supplemented with 0.01 M EDTA and 0.5 mM BHT, and 
cytosolic fractions were used for sulfonation assays.
BPA Sulfonation Activity
Activity assays for each liver tissue were performed in duplicate, and the average of 
duplicate data was analyzed. Human liver cytosols were incubated with radiolabeled 
sulfonyl donor [35S]-3′-phosphoadenosine-5′-phosphosulfate (35S-PAPS, 4 μM) and 4 μM 
BPA in 20 mM potassium phosphate (pH 7.0). Reaction mixture was incubated for 30 min at 
37°C, stopped by heating in boiling water for 30 sec, and centrifuged at 14,000*g for 1 min 
to pellet the protein. To separate reaction components, supernatant was injected onto 
Phenomenex Synergi Polar-RP column (50 x 2.00 mm, 4 micron). A linear gradient of 15–
80% acetonitrile and 20 mM potassium phosphate (pH 2.7) in 8 min was used as mobile 
phase at 1 mL/min flow to separate excess 35S-PAPS from 35S-BPA. 35S-labeled peaks were 
quantified on a flow scintillation analyzer (Packard Bioscience, 500 TR series) with Perkin-
Elmer Ultima Flo-M scintillation cocktail. 35S-PAPS was eluted at 0.5 min, 35S-BPA-
disulfate at 4.2 min, and 35S-BPA-monosulfate at 4.8 min.
Probe Sulfonation Activity Assays
Sulfonation assays for probe substrates was performed as described in (Yalcin et al. 2013). 
Briefly, cytosolic fraction of liver tissue was incubated with radiolabeled sulfonyl 
donor 35S-PAPS (4 μM) and a prototype substrate. Sulfated products of p-nitrophenol (pNP, 
4 μM), estradiol (20 nM), and Dehydroepiandrosterone (DHEA, 10 μM) were separated on 
Synergi Polar-RP column (Phenomenex, Torrance, CA) and dopamine-sulfate on a Hypersil 
Duet C18/SAX column (Thermo Fisher Scientific). Radiolabeling was detected and 
quantified on a flow scintillation analyzer (500 TR series; Packard Bioscience, Meriden, 
CT) with PerkinElmer Ultima Flo-M scintillation cocktail.
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Western Blotting
Cytosols (50 μg) were electrophoretically separated by SDS-PAGE and transferred onto a 
polyvinylidene difluoride membrane. After blocking the membrane with non-fat dry milk, 
blot was incubated with SULT1A1 antibody (Santa Cruz Biotechnology, TX, USA) and 
subsequently with corresponding HRP-labeled secondary antibody. Blots were visualized 
using Pierce ECL-Plus Western blot detection reagent (Thermo Fisher Scientific, Rockford, 
IL, USA) and quantified using ImageQuant software (Bio-Rad, Hercules, CA).
Statistical analysis
Statistical analysis was performed using the GraphPad Prism 6 software. The correlation 
plots in human and mouse models were obtained by Pearson correlation and multiple 
regression analysis, respectively. The sample-sets were tested for normal distribution. For 
sample-sets without normality distribution, Logn transformation was performed to ensure all 
data set normality. A two-way ANOVA was performed followed by Duncan’s multiple 
range post hoc test. Probability (p) values less than 0.05 were considered significant.
Results
BPA sulfonation in non-fatty and diseased human livers
BPA sulfonation was quantified in 81 human liver samples from individuals diagnosed with 
steatosis (n=13), diabetes (n=4), diabetic cirrhosis (n=22), alcoholic cirrhosis (n=22), and 
non-fatty (n=20) livers (Supplemental Table 1). BPA sulfonation in non-fatty normal liver 
tissue cytosolic fraction averaged 7.99 pmol/min/mg. Hepatic BPA sulfonation was 
significantly lowered in steatosis (23% activity remaining), diabetes (8%), diabetes cirrhosis 
(16%), and alcoholic cirrhosis (18%) relative to non-fatty livers from healthy subjects 
(Figure 1). There was no statistical difference observed in BPA sulfonation between the 
genders.
Sulfotransferase isoform activity in liver cytosolic fractions from WT and ob/ob mice
The effect of obesity and fasting on the activity of four major mouse liver cytosolic 
sulfotransferases was determined by probe substrate sulfonation (as described in material 
and methods) in C57BL/6 and ob/ob mice, fed or food-withheld for 24 hours (n=3–4/group). 
The rationale to evaluate Sult activity in both fed and fasted mice was because fasting 
induces hepatic steatosis, which is exacerbated in obese mice. Our group has demonstrated 
that hepatic triglycerides are elevated in ob/ob mice after a 24 hour fast (Xu et al., 2012). 
Fasting did not alter pNP-sulfonation (Sult1a1) or dopamine-sulfonation (Sult1a3) activity 
in WT mice, and DHEA-sulfonation (Sult2a1) activity remained undetectable in WT mouse 
livers under both fed (ad libitum) and fasted conditions (Fig. 2A). Under fed conditions, 
ob/ob mouse livers demonstrated somewhat lower pNP-sulfonation activity (Sult1a1) (78%), 
but higher estradiol-sulfonation (Sult1e1) (5 fold) and DHEA-sulfonation (Sult2a1) (4 fold) 
with a similar dopamine-sulfonation (Sult1a3) activity (Fig. 2A) as compared to their WT 
counterparts. As with the WT mice, fasting did not alter Sult1a1 or Sult1a3 activity in ob/ob 
mice, but increased DHEA-sulfonation (Sult2a1) activity in ob/ob mouse livers (1.5 fold 
over ob/ob fed livers) (Fig. 2A). Although Sult1a1 protein expression was undetectable in 
Yalcin et al. Page 5
Toxicol Appl Pharmacol. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
ob/ob mouse livers (Fig. 2B), we were able to measure pNP sulfonation (Fig. 2A) potentially 
due to contribution of other mouse Sult isoforms in pNP sulfonation. According to Tabrett 
and Coughtrie (2003), sulfonation of pNP by purified recombinant human SULT1B1 was 
significant at concentrations of 4-nitrophenol less than 10 μM, while pNP sulfonation by 
recombinant SULT1E1, SULT1A3, and SULT2A1 occurred only at higher substrate 
concentrations (~100 μM). The substrate selectivity of mouse sulfotransferases has not been 
studied due to lack of recombinant preparations of the mouse Sult isoforms.
Effect of obesity and fasting on Sult1a1 protein expression in livers of C57BL/6 and ob/ob 
mice
Sult1a1 protein expression was barely detectable in ob/ob mice compared to wild-type 
C57BL/6 mice, regardless of feeding status (p ≤ 0.05) (Figure 2B). The observed decrease in 
Sult1a1 protein expression in obese mice is a likely explanation for decreased BPA-
sulfonation activity in livers of these mice.
BPA sulfonation in WT and ob/ob mouse livers
The effect of obesity and fasting on BPA sulfonation was determined using WT and ob/ob 
adult male mice. BPA sulfonation in mouse liver cytosols formed two products: monosulfate 
of BPA (BPS-S, 23%) and bis-sulfate of BPA (BPA-2S, 77%), with BPA-2S:BPA-S ratio 
being 3.35. Relative to WT mice, total BPA sulfonation was significantly diminished in 
ob/ob mouse livers accompanied with a decreased BPA-2S:BPA-S to 1.85. Fasting 
significantly decreased BPA sulfonation in WT livers to about 75% of fed control, without 
changing the BPA-2S:BPA-S. Combined with these results, there is a potential for decreased 
renal excretion of BPA in obesity as modeled by the ob/ob mice and 24-hr fasting. Although 
upon fasting, total BPA sulfonation remained unchanged in ob/ob livers, it increased 
BPA-2S: BPA-S, to 2.57 as compared 1.85 in the ob/ob fed controls (Fig. 2C).
Correlation of BPA sulfonation versus probe substrate sulfonation in human livers
In vitro, BPA is sulfonated by multiple human sulfotransferase isoforms; SULT1A1, 
SULT2A1, and SULT1E1 with SULT1A1 possessing the highest reaction rate (Nishiyama 
et al., 2002). A linear correlation between BPA versus pNP sulfonation was detected in 
normal and diseased human liver cytosols (Fig. 3A). At 4 μM (Tabrett and Coughtrie, 2003), 
pNP sulfonation is known to be catalyzed mainly by SULT1A1, thus linear correlation 
indicates that SULT1A1 is potentially responsible for BPA sulfonation in these human liver 
cytosol samples. In contrast, BPA sulfonation did not yield significant linear correlation 
with DHEA- (Fig. 3D), while significantly correlated with dopamine- (Fig. 3B), as well as 
estradiol-sulfonation (Fig. 3C). However, correlation of BPA sulfonation with pNP 
sulfonation (SULT1A1 activity) remained the highest correlation of the three indicating 
SULT1A1 as the primary SULT isoform responsible for BPA sulfonation.
Correlation of BPA sulfonation with SULT isoform protein expression in human livers
It has been shown that sulfotransferase isoforms can compensate for the absence of other 
isoforms with respect to substrate sulfonation. Hence, it was also important to determine 
whether protein expression of SULT isoforms in human livers correlates with extent of BPA 
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sulfonation. As demonstrated in Fig. 4, in human livers, BPA sulfonation significantly 
correlated with SULT1A1 protein (Fig. 4A) expression only. Correlation analysis of BPA 
sulfonation versus SULT1A3 (Fig. 4B), 1E1 (Fig. 4C) and 2A1 (Fig. 4D) protein expression 
remained non-significant. These observations further indicate that SULT1A1 primarily 
sulfonates BPA in human liver.
Human and mouse BPA sulfonation by liver cytosolic sulfotransferases is similar
One of the aims of the present study is to determine whether BPA sulfonation changed 
similarly in normal and steatotic, human and mouse models. Hence, BPA sulfonation in 
male human normal (n=10) and steatotic (n=10) livers and male mouse WT (n=6) and ob/ob 
(n=6) livers was compared. As depicted in Fig. 1, 2A, 2C and 5A, BPA and pNP sulfonation 
are significantly downregulated in human steatotic samples as well as in ob/ob mouse livers. 
These observations indicate that presence of increased fat in livers can change sulfonation of 
BPA in both human and rodents. Total BPA sulfonation in ob/ob mouse livers significantly 
correlated with Sult1a1 protein expression (Fig. 5B) indicating Sult1a1 as the primary 
sulfotransferase isoform sulfonating BPA in mouse livers.
Correlation of BPA versus pNP sulfonation in WT and ob/ob mouse livers
A linear correlation was detected between total BPA (4 M) versus pNP (4 μM) sulfonation 
(Fig. 6A) and dopamine (Fig. 6B) sulfonation in control and ob/ob mouse liver cytosols. In 
contrast to human livers, although significant, mouse estradiol versus BPA sulfonation 
yielded an inverse correlation (Fig. 6C). Thus, Sult1a1 and/or Sult1a3, and not Sult1e1, 
contribute to total BPA sulfonation in mouse liver.
Mouse BPA sulfonation decreases with increasing liver triglycerides, and serum lipid and 
glucose content
Increased serum triglycerides (TG), non-esterified free fatty acids (NEFA) and glucose 
along with increased hepatic TG and NEFA are characteristic of obesity/steatosis/metabolic 
syndrome. Our previous work with the fasted ob/ob mouse model provides a spectrum of 
serum glucose and lipid concentrations, as well as elevated liver triglyceride content from 
the wild-type fed mouse to the fasted obese mouse (Xu et al., 2012). Thus, we characterized 
livers from this sample set to better understand whether serum markers associated with fatty 
liver disease correspond to BPA sulfonation. Overall, BPA sulfonation significantly 
decreased in steatotic human and mouse samples (Fig. 5A). To determine whether 
biochemical parameters significantly contributed to observed decreases in BPA sulfonation, 
BPA sulfonation was compared with individual biochemical parameters in WT and ob/ob, 
fed and fasted mice. Fasting results in an increased hepatic TG and NEFA content which has 
been previously described (Xu et al., 2012). BPA sulfonation inversely correlated with 
serum glucose levels (Fig. 7A). As seen in Fig. 7B, BPA sulfonation demonstrated a 
significant inverse correlation with serum and liver TG. BPA sulfonation inversely 
correlated with serum but not liver NEFA (Fig. 7C). Above observations indicate that the 
biochemical changes in lipid and glucose concentrations in steatotic models potentially alter 
the sulfotransferase activity and hence, total BPA sulfonation in the livers.
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Steatosis and BPA sulfonation in human and mouse
As shown in Fig. 3D, BPA sulfonation did not significantly correlate with DHEA 
sulfonation/SULT2A1 activity in human livers (normal and diseased). However, a 
correlation analysis with segregated diseased conditions revealed a near-significant 
correlation between BPA and DHEA sulfonation in male steatotic and diabetic livers (Fig. 
8A and Supp Fig. 1) indicating SULT2A1 could also potentially contribute to BPA 
sulfonation in steatotic and diabetic livers. It is also interesting to note that BPA versus 
DHEA sulfonation remained insignificant in other disease conditions of diabetes-cirrhosis, 
and alcohol cirrhosis (Supp. Fig. 2). DHEA versus BPA sulfonation correlation analysis was 
performed in ob/ob mouse samples to determine whether animal model of steatosis/
hyperglycemia also demonstrated similar trends. It is important to note that in our 
experiments, DHEA sulfonation was detectable only in ob/ob liver cytosolic fraction, while 
WT cytosols showed no detectable sulfonation of DHEA. Correlation analysis between 
DHEA and BPA sulfonation, in ob/ob liver cytosols set demonstrated a near-significant 
correlation (Fig. 8B).
Discussion
The present study describes BPA sulfonation in normal and diseased human and mouse liver 
tissue. Nishiyama et al., 2002, studied participation of human SULTs in BPA metabolism 
using purified recombinant human sulfotransferases. SULT1A1 demonstrated highest 
kcat/km (574 min−1mM−1) and lowest km (4.7 μM) values followed by SULT2A1 and 1E1, 
while SULT1A3 had no effect on BPA sulfonation. In agreement with these data, human 
liver SULT1A1 (4 μM pNP) activity showed the best correlation towards BPA sulfonation 
in human liver cytosols (Fig. 3A). SULT1A1 protein decreases progressively from steatotic 
to cirrhotic liver tissues (Yalcin et al., 2013) similar to the significant decrease in BPA 
sulfonation in diseased tissues observed herein. These observations along with a significant 
correlation between pNP and BPA sulfonation suggest primarily SULT1A1 mediated BPA 
sulfonation in human liver. SULT1A3 activity also significantly correlated with BPA 
sulfonation in human liver cytosol (Fig. 3B), indicating a potential role for the phenol-
preferring cytosolic SULT1A family in BPA sulfonation. Interestingly, SULT1E1 activity 
(Fig. 3C) also correlated significantly with BPA sulfonation. However, SULT1E1 
expression and contribution to sulfonation in liver is lower than the other sulfotransferases 
(Riches et al., 2009; Yalcin et al., 2013), hence contribution to BPA sulfonation may be 
insignificant. BPA treatment has also been shown to inhibit SULT1E1 to a greater extent 
than SULT1A1 in vitro in hepatocytes (Hanet et al., 2008), further diminishing expected 
SULT1E1 contribution. The specificity of probe substrates for SULT1A1 (Tabrett and 
Coughtrie, 2003), SULT1A3 (Yasuda et al., 2007), SULT2A1 (Huang et al., 2010), and 
SULT1E1 (Falany et al., 1995) isoforms were shown using purified recombinant enzymes. 
In addition, we showed the specificity and selectivity of anti-SULT1A1 and anti-SULT1A3 
antibodies using recombinant protein and human cytosolic liver fractions (Yalcin et al., 
2013). Anti-SULT2A1 (purchased from Abcam) and anti-SULT1E1 (Aviva Systems 
Biology) antibodies had previously been tested on human livers.
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Compared to human, the contribution of sulfotransferase isoforms to BPA sulfonation in 
mouse is relatively unknown, with Sult1a1 being suspected as the major contributing 
isoform to BPA sulfonation. Data obtained in this study after correlating BPA sulfonation 
with probe substrate sulfonation indicates that in mouse livers, as in humans, Sult1a1 and 
1a3 are primarily involved in BPA sulfonation (Fig. 6A and 6B). In steatotic ob/ob mouse, 
BPA sulfonation was significantly decreased along with Sult1a1 protein expression further 
suggesting Sult1a1 involvement. However, unlike human, correlation of Sult1e1 activity 
with BPA sulfonation in mouse liver cytosols demonstrated an inverse correlation (Fig. 6C). 
Significant induction of Sult1e1/estradiol activity in ob/ob mice could potentially bias the 
correlation analysis and should be evaluated further. Ob/ob livers show a detectable DHEA 
sulfonation and a significant correlation between DHEA and BPA sulfonation, potentially 
due to significantly increased liver Sult2a1 expression relative to WT livers (data not shown) 
and indicating a Sult2a1 mediated BPA sulfonation in steatosis. We also observed a similar 
trend in diseased human livers, with SULT2A1 activity significantly correlating with BPA 
sulfonation only in steatotic and steatotic diabetic livers, indicating a shift in BPA 
sulfonation in these livers. These observations are in line with higher serum BPA 
concentration in obese women than lean counterparts, potentially due to changes in BPA 
metabolism in part mediated by SULTs (Takeuchi et al. 2004).
Increasing fasting duration decreases urinary total BPA concentrations in humans 
(Christensen et al. 2012). As shown in the present study, decreased Sult1a1 expression along 
with BPA sulfonation in a murine model could explain the observation (Fig. 2B). However, 
fasting did not alter Sult1a1 expression or further decrease BPA sulfonation in ob/ob mouse 
(Fig. 3B and 3C). This unchanged BPA sulfonation upon fasting in ob/ob mouse livers could 
potentially be explained as follows: Fasting down regulates Sult1a1 activity resulting in 
potential compensation from Sult2a1. In the absence of one isoform, sulfonation of substrate 
is compensated by another isoform such as SULT12A1 mediated sulfonation of estradiol, a 
prototypical SULT1E1 substrate (Riches et al. 2009). It is possible in ob/ob mouse livers, 
where BPA sulfonation is Sult2a1 mediated; fasting induction of Sult2a1 keeps total BPA 
sulfonation unchanged (Fig. 2C). Short term fasting increases serum and hepatic TG and 
NEFA content and in the present study; ob/ob fasted mice have the highest TG and NEFA 
content (Xu et al., 2012) in contrast to caloric restriction where these parameters decrease 
(Kulkarni et al., 2013). BPA sulfonation inversely correlated with most of serum and hepatic 
lipid parameters, as well as, glucose indicating that the metabolic state of the liver is 
important in determining the extent of BPA sulfonation. To date, there are have been 
multiple published studies that have associated aspects of metabolic disease with urine BPA 
concentrations (Rochester, 2013; Lakind et al., 2014). While these do not specifically 
address risk for liver disease, the studies are evaluating common risk factors associated with 
NAFLD. For example, a cross-sectional evaluation of urine samples and data from 1455 
adults aged 18–74 years from the 2003–2004 National Health and Nutrition Examination 
Survey 2003–2004 reported higher urinary total BPA concentrations in association with 
cardiovascular diagnoses, diabetes, and clinically abnormal concentrations of the liver 
enzymes, i.e. gamma-glutamyltransferase and alkaline phosphatase (Lang et al., 2008). In a 
separate cross-sectional study analyzing urine from 2747 adults (aged 18–74) using pooled 
data from the 2003/04 and 2005/06 National Health and Nutrition Examination Surveys, 
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higher BPA exposure was associated with general and central obesity in the general adult 
population of the United States (Carwile and Michels, 2011). The association between total 
urinary BPA concentration and generalized obesity or abdominal obesity has also been 
observed in Chinese populations (Wang et al., 2012), children and adolescents (Trasande et 
al., 2012; Bhandari et al., 2013; Wang et al., 2013). Recent work also demonstrated an 
association between urinary BPA content and adverse liver effects in young boys (Khalil et 
al., 2014). Given that the latter cited studies are cross-sectional in design, there has been 
concern that reverse causality may be important (Lang et al., 2008). There is recent 
epidemiological evidence to support this concern. Recent work evaluating the CHAMACOS 
prenatal and postnatal cohort observed that higher urinary BPA concentrations at 9 years of 
age were associated with increased adiposity at 9 years, whereas increasing BPA 
concentrations in mothers during pregnancy were associated with decreased BMI, body fat, 
and overweight/obesity among their daughters at 9 years of age (Harley et al., 2013). Our 
work herein supports the notion that reverse causality could occur, which could be due to 
decreased capacity for BPA biotransformation in association with fatty liver. We 
acknowledge that additional work addressing BPA glucuronidation is needed. However, 
these findings using livers from both human and rodent disease models demonstrate 
decreased BPA biotransformation and strongly argue for additional work to understand the 
contribution of liver disease to BPA clearance, especially in obesity and conditions of 
insulin resistance.
In summary, the data herein report a significant decrease in BPA sulfonation in liver 
samples from humans diagnosed with steatosis, diabetes, and cirrhosis via decreased 
sulfotransferase enzyme activity, primarily SULT1A1 expression and activity. Furthermore, 
BPA sulfonation is directly correlated with SULT2A1/Sult2a1 activity in human and mouse 
steatotic livers and not cirrhotic livers. These new results are especially important 
considering that BPA-sulfate conjugates have been detected in human urine, suggesting that 
BPA sulfonation occurs even at common (and relatively low) BPA exposures.
Conclusion
We report novel findings that liver disease negatively impacts BPA biotransformation. 
Decreased BPA sulfonation in association with impaired liver function or increased hepatic 
lipid content and markers of metabolic syndrome may result in increased free BPA or total 
urinary BPA levels.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Present study demonstrates that hepatic SULT 1A1/1A3 are primarily sulfonate 
BPA in mouse and human.
• Hepatic BPA sulfonation is profoundly reduced steatosis, diabetes and cirrhosis.
• With BPA-S detectable in urine under low or common exposures, these findings 
are novel and important.
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Figure 1. Bisphenol A (BPA) sulfonation is decreased in cytosolic fractions isolated from diseased 
human livers
Each data point represents a single tissue (average of determinations) categorized by gender 
and disease type. (n=20 for nonfatty, n=13 for steatosis, n=4 for diabetes, n=21 diabetic 
cirrhosis, and n=21 for alcohol cirrhosis). Females are displayed as black diamonds (◆), 
males as white diamonds (□). BPA sulfonation was determined by incubating 4 μM 
bisphenol A with human liver cytosols for 30 min in the presence of the 35S-labeled cofactor 
3′-Phosphoadenosine-5′-phosphosulfate (PAPS). The reaction rate was calculated as product 
formation (pmol)/reaction time (min) / amount of enzyme used (mg). Asterisks (*) represent 
statistically significant differences between non-fatty and diseased human livers.
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Figure 2. Obesity decreases BPA and pNP sulfonation in mice
(A) Sulfotransferase probe substrate activities in WT and ob/ob mouse livers-C57BL/6 
and ob/ob mice (n=8/group) were either fed ad libitum or food withheld for 24 hours. 
Sult1a1, Sult1a3, Sult1e1 and Sult2a1 activity was determined using probe substrates pNP, 
dopamine, estradiol and DHEA respectively in liver cytosols as described in methods. (B) 
Sult1a1 protein expression in WT and ob/ob mouse livers- Representative western blot 
for Sult1a1 protein expression was determined in liver cytosols from WT and ob/ob mice 
fed ad libitum or food withheld for 24 hours with gapdh as the loading control. Blots were 
quantified using ImageJ software. (C) BPA sulfonation in C57BL/6 and ob/ob mouse 
liver cytosols under fed ad libitum and fasted conditions. BPA sulfonation (BPA-
monosulfate, BPA-disulfate) was determined in WT and ob/ob, fed or fasted mouse livers by 
incubating 4 μM bisphenol A with mouse liver cytosols for 30 min in the presence of the 
35S-labeled cofactor PAPS. Reaction components separated with HPLC and 35S labeled 
compounds were detected with a radiochemical detector. The reaction rate was calculated as 
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product formation (pmol) / reaction time (min) / amount of enzyme used (mg). p<0.05 was 
considered statistically significant. “*” reflects significant difference between the fed and 
fasted groups whereas “#” reflects a significant difference between the genotypes.
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Figure 3. 
Human BPA sulfonation correlates significantly with (A) SULT1A1 probe activity, (B) 
SULT1A3 probe activity, and (C) SULT1E1 probe activity, but not (D) SULT2A1 
probe activity. The correlation between probe substrate and BPA sulfonation in human 
livers were obtained by Pearson correlation using GrapPad Prism. p< 0.05 were considered 
significant.
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Figure 4. Human BPA sulfonation correlates significantly only with (A) SULT1A1 protein 
expression and not (B) 1A3 or (C) 1E1 or (D) SULT2A1 protein expression
Correlation analysis of total BPA sulfate in human livers (control and diseased) with (A) 
SULT1A1, (B) 1A3, (C) 1E1 and (D) 2A1 protein levels. The correlation analyses in human 
livers were obtained by Pearson correlation using GraphPad Prism 6. p<0.05 was considered 
statistically significant.
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Figure 5. Human and mouse BPA sulfonation rates are comparable
(A) pNP and BPA sulfation in normal and fatty livers in human and mouse (males 
only). Relative sulfonation of BPA and pNP (Sult1a1/SULT1A1 probe substrate) in male 
human normal (n=10) and steatotic (n=7) and mouse normal (n=6; 3 fed/3 fasted) and 
steatotic (n=6;3 fed/3 fasted) liver cytosols. (B) Correlation analysis of total BPA 
sulfonation versus Sult1a1 protein in WT and obese fed and fasted mouse liver cytosols 
(n=3/group). The correlation analyses in mouse livers were obtained by Pearson correlation 
using GrapPad Prism 6. p<0.05 was considered statistically significant.
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Figure 6. 
BPA sulfonation in mouse liver highly correlates with Sult1a1 and Sult1a3 activity. 
Correlation of BPA versus (A) p-nitrophenol, (B) dopamine, (C) estradiol sulfonation 
in WT and ob/ob mice. Correlations were obtained by Pearson correlation using GraphPad 
Prism 6. P< 0.05 were considered significant
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Figure 7. Increased triglyceride and glucose concentrations are associated with decreased BPA 
sulfonation
Corrrelation of total BPA sulfonation in WT and ob/ob fed and fast (n=3/group) mouse 
cytosol with (A) serum glucose (mg/dl), (B) serum (uM) and liver triglycerides (mg/g liver 
wt) (TG) and (C) serum (MEq) and liver non-esterified fatty acids (NEFA) (MEq/gm liver 
wt). Correlations were obtained by Pearson correlation using GraphPad Prism 6. P< 0.05 
were considered significant.
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Figure 8. 
BPA sulfonation correlates with dehydroepiandrosterone (DHEA) sulfonation in male 
(A) human steatotic livers (n=7) and (B) ob/ob fed and fast (n=3/group) mouse livers. 
Correlations were obtained by Pearson correlation using GraphPad Prism 6. P< 0.05 were 
considered significant.
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